Laura J Tandeske

US Patent:

6632601, Oct 14, 2003

Filed:

Jun 14, 2001

Appl. No.:

09/881654

Inventors:

David Y. Chien - Alamo CA
Phillip Arcangel - Oakland CA
Laura Tandeske - San Leandro CA
Carlos George-Nascimento - Walnut Creek CA
Doris Coit - Petaluma CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C12Q 170

US Classification:

435 5, 436518, 435 23

Abstract:

HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays.

US Patent:

6797809, Sep 28, 2004

Filed:

Aug 8, 2003

Appl. No.:

10/637323

Inventors:

David Y. Chien - Alamo CA
Phillip Arcangel - Oakland CA
Laura Tandeske - San Leandro CA
Carlos George-Nascimento - Walnut Creek CA
Doris Coit - Petaluma CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C07K 1700

US Classification:

530350, 530300, 4241891, 4242021, 4242281, 436518

Abstract:

HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays.

US Patent:

7241879, Jul 10, 2007

Filed:

Jul 26, 2004

Appl. No.:

10/899715

Inventors:

David Y. Chien - Alamo CA, US
Phillip Arcangel - Oakland CA, US
Laura Tandeske - San Leandro CA, US
Carlos George-Nascimento - Walnut Creek CA, US
Doris Coit - Petaluma CA, US

Assignee:

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

International Classification:

C07H 21/04

US Classification:

536 234, 435 697, 435328, 530350

Abstract:

HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays.

US Patent:

7319144, Jan 15, 2008

Filed:

Aug 19, 2003

Appl. No.:

10/643853

Inventors:

David Y. Chien - Alamo CA, US
Phillip Arcangel - Oakland CA, US
Laura Tandeske - San Leandro CA, US
Carlos George-Nascimento - Walnut Creek CA, US
Doris Coit - Petaluma CA, US

Assignee:

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

International Classification:

C07H 21/00
C12N 15/00
C12N 15/09
C12N 15/33
C12N 15/51
C12P 21/00
A61K 39/00
A61K 39/29

US Classification:

536 2372, 536 234, 435 691, 435 693, 435 697, 4353201, 4241841, 4241861, 4241891, 4241921, 4242281

Abstract:

The invention relates to a method of detecting HCV infection in a biological sample, the method comprising providing an immunoassay solid support, comprising an HCV anti-core antibody, an antigen comprising an HCV NS3/4epitope, and an HCV multiple epitope fusion antigen, that can detect both HCV antigens and antibodies present in a sample. The invention also includes polynucleotides encoding multiple epitope fusion antigens for use in the assay, recombinant vectors and host cells comprising such polynucleotides, and methods of producing the multiple epitope fusion antigens.

US Patent:

7871625, Jan 18, 2011

Filed:

Aug 26, 2005

Appl. No.:

11/661577

Inventors:

David Chien - Alamo CA, US
Doris Coit - Petaluma CA, US
Carlos George-Nascimento - Walnut Creek CA, US
Sansan Lin - Albany CA, US
Laura Tandeske - San Leandro CA, US

Assignee:

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

International Classification:

A61K 39/00
C12N 15/00

US Classification:

4241891, 4242011, 4242281, 435 691

Abstract:

Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.

US Patent:

20020192639, Dec 19, 2002

Filed:

Jun 14, 2001

Appl. No.:

09/881239

Inventors:

David Chien - Alamo CA, US
Phillip Arcangel - Oakland CA, US
Laura Tandeske - San Leandro CA, US
Carlos George-Nascimento - Walnut Creek CA, US
Doris Coit - Petaluma CA, US

International Classification:

C12Q001/70
C12M001/34
C12M003/00

US Classification:

435/005000, 435/287200

Abstract:

An HCV core antigen and NS3/4a antibody combination assay that can detect both HCV antigens and antibodies present in a sample using a single solid matrix, is provided, as well as immunoassay solid supports for use in the assay.